Our purpose is to make use of a novel means of generating immunogenic tumor variants for the immunotherapy of metastasis. The animal model described is one which attempts to mimic the clinical situation, where metastasis is the major cause of death. Our protocols include surgical removal of the primary tumor followed by treatment with cyclophosphamide to inhibit putative suppressor T cells. This is followed by adoptive immunization with syngeneic lymphocytes activated with immunogenic clones derived from the parent tumor by mutagen or UV light treatment. These immunogenic clones generate allogeneic-like cytotoxic T cell responses which protect against parent tumor challenge in vivo. Preliminary data have demonstrated that adoptive immunotherapy can 'cure' as many as 60% of animals bearing one of the most aggressive metastatic murine tumors known. In addition, we have early evidence that active immunization of animals with established metastasis with viable immunogenic clones, may also be an effective therapeutic modality. We plan to further assess the use of IL-2 in combination with adoptive or active immunotherapy for the treatment of established metastasis, an attempt will also be made to assess the usefullness of adoptive and/or active immunization in conjunction with non-specific macrophage activation using MTP-PE. Experiments designed to define at least in part, the nature of the mutagen or UV induced antigen will also be performed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA041525-03
Application #
3182105
Study Section
Experimental Immunology Study Section (EI)
Project Start
1986-08-01
Project End
1990-07-31
Budget Start
1988-08-01
Budget End
1989-07-31
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Huang, S; Xie, K; Bucana, C D et al. (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2:1969-79
Jean, D; Bar-Eli, M; Huang, S et al. (1996) A cysteine proteinase, which cleaves human C3, the third component of complement, is involved in tumorigenicity and metastasis of human melanoma. Cancer Res 56:254-8
Hudson, J M; Frade, R; Bar-Eli, M (1995) Wild-type p53 regulates its own transcription in a cell-type specific manner. DNA Cell Biol 14:759-66
Huang, S; Xie, K; Singh, R K et al. (1995) Suppression of tumor growth and metastasis of murine renal adenocarcinoma by syngeneic fibroblasts genetically engineered to secrete the JE/MCP-1 cytokine. J Interferon Cytokine Res 15:655-65
Luca, M; Xie, S; Gutman, M et al. (1995) Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene 11:1399-402
Singh, R K; Gutman, M; Reich, R et al. (1995) Ultraviolet B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin 8. Cancer Res 55:3669-74
Radinsky, R; Fidler, I J; Price, J E et al. (1994) Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 9:1877-83
Huang, S; Singh, R K; Xie, K et al. (1994) Expression of the JE/MCP-1 gene suppresses metastatic potential in murine colon carcinoma cells. Cancer Immunol Immunother 39:231-8
Gutman, M; Singh, R K; Radinsky, R et al. (1994) Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 14:1759-65
Ellerhorst, J A; Frost, P; Abbruzzese, J L et al. (1993) 2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation. Br J Cancer 67:209-15

Showing the most recent 10 out of 22 publications